Celltrion plans to invest across its pharmaceutical business up to 2030, creating an estimated 110,000 new jobs in the process and launching 20 products.
Roche’s acquisition of Spark was announced at the start of the year but closing the deal has proved difficult after a third delay incurred to give the FTC extra review time.
Diverse leadership provides more opportunity for innovation and higher performance in financial return, says diversity and inclusion chair and biotech executive.
